drugset
drugset / Trial / NCT04540900

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

NCT04540900 ↗

Phase 1 Active not recruiting 85 enrolled Krystal Biotech, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

Timeline

Start
2020-10-07
Primary completion
2024-10-16
Completion
2029-05-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator KB301 Unknown — Other

Indications

No indication recorded.